tiprankstipranks
Trending News
More News >

AdAlta Limited Commences Rights Trading to Support Growth in Cancer Immunotherapy

Story Highlights
AdAlta Limited Commences Rights Trading to Support Growth in Cancer Immunotherapy

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from AdAlta Ltd. ( (AU:1AD) ).

AdAlta Limited has announced the commencement of rights trading on the ASX under the code 1ADR as part of a renounceable rights issue. This offer aims to raise approximately $1.29 million by issuing new shares and options to eligible shareholders, with the proceeds intended to support the company’s ongoing operations and strategic initiatives. The rights trading period will end on May 21, 2025. This move is expected to bolster AdAlta’s financial position, enabling further investment in their innovative cellular immunotherapy projects, thereby enhancing their market positioning in the high-growth segment of solid cancer treatments.

More about AdAlta Ltd.

AdAlta Limited is a clinical stage biotechnology company focused on developing effective cellular immunotherapies for the treatment of solid cancers. The company leverages a strategy that integrates Asian T cell therapy development with Australia’s clinical and manufacturing capabilities. AdAlta in-licenses products from Asia and invests in US FDA regulated manufacturing and Phase I clinical studies, aiming to position these products for further development and commercialization by larger biopharmaceutical companies. The company targets the underserved solid tumor market, which constitutes 90% of cancers, and is projected to grow significantly. AdAlta’s innovative approach includes their first-in-class fusion protein, AD-214, for fibrotic diseases.

Average Trading Volume: 658,002

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$3.86M

See more insights into 1AD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1